APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Antianginal Agents

Compare research editions
View pricing & licenses

Selected research

Industry Research

Antianginal Agents Industry Research Report 2026

Report ID 173965580529 December 2025149 pages

Choose your research edition.

Industry ResearchAntianginal Agents Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Antianginal Agents Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal Antianginal Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antianginal Agents Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Antianginal Agents Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global Antianginal Agents market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Antianginal Agents is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Antianginal Agents is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Antianginal Agents is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Antianginal Agents include Teva, Sun Pharmaceutical, Shandong Fangming Pharmaceutical Group, Sandoz, ReYoung Pharmaceutical, Merck, Pfizer, AstraZeneca and Unique Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Antianginal Agents market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Antianginal Agents Market by Company

Teva

Sun Pharmaceutical

Shandong Fangming Pharmaceutical Group

Sandoz

ReYoung Pharmaceutical

Merck

Pfizer

AstraZeneca

Unique Pharmaceuticals

Troikaa

Taj pharmaceutical

Square Pharmaceuticals

Pharmaoffer.com

Nesher Pharmaceuticals

Mylan N.V.

Ipca Laboratories

Intas Pharmaceuticals

Hikma Pharmaceuticals

Globus Remedies

Glenmark Pharmaceuticals

Espero BioPharma

Elite Pharmaceutical Solution Inc.

Aurobindo Pharma

Athenex

AMRI

ACETO

Antianginal Agents Segment by Type

Beta Blockers

Calcium Channel Blockers

Nitrates

Antianginal Agents Segment by Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Antianginal Agents Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antianginal Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antianginal Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antianginal Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Antianginal Agents manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Antianginal Agents by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Antianginal Agents in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Antianginal Agents Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Antianginal Agents Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Antianginal Agents Sales Market Share by Manufacturers (2021-2026) Table 8. Global Antianginal Agents Revenue of Manufacturers (2021-2026) Table 9. Global Antianginal Agents Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Antianginal Agents Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Antianginal Agents Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Antianginal Agents, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Antianginal Agents, Product Type & Application Table 14. Global Antianginal Agents Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Antianginal Agents by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Teva Company Information Table 19. Teva Business Overview Table 20. Teva Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Teva Antianginal Agents Product Portfolio Table 22. Teva Recent Developments Table 23. Sun Pharmaceutical Company Information Table 24. Sun Pharmaceutical Business Overview Table 25. Sun Pharmaceutical Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Sun Pharmaceutical Antianginal Agents Product Portfolio Table 27. Sun Pharmaceutical Recent Developments Table 28. Shandong Fangming Pharmaceutical Group Company Information Table 29. Shandong Fangming Pharmaceutical Group Business Overview Table 30. Shandong Fangming Pharmaceutical Group Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Shandong Fangming Pharmaceutical Group Antianginal Agents Product Portfolio Table 32. Shandong Fangming Pharmaceutical Group Recent Developments Table 33. Sandoz Company Information Table 34. Sandoz Business Overview Table 35. Sandoz Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Sandoz Antianginal Agents Product Portfolio Table 37. Sandoz Recent Developments Table 38. ReYoung Pharmaceutical Company Information Table 39. ReYoung Pharmaceutical Business Overview Table 40. ReYoung Pharmaceutical Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. ReYoung Pharmaceutical Antianginal Agents Product Portfolio Table 42. ReYoung Pharmaceutical Recent Developments Table 43. Merck Company Information Table 44. Merck Business Overview Table 45. Merck Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Merck Antianginal Agents Product Portfolio Table 47. Merck Recent Developments Table 48. Pfizer Company Information Table 49. Pfizer Business Overview Table 50. Pfizer Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Pfizer Antianginal Agents Product Portfolio Table 52. Pfizer Recent Developments Table 53. AstraZeneca Company Information Table 54. AstraZeneca Business Overview Table 55. AstraZeneca Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. AstraZeneca Antianginal Agents Product Portfolio Table 57. AstraZeneca Recent Developments Table 58. Unique Pharmaceuticals Company Information Table 59. Unique Pharmaceuticals Business Overview Table 60. Unique Pharmaceuticals Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Unique Pharmaceuticals Antianginal Agents Product Portfolio Table 62. Unique Pharmaceuticals Recent Developments Table 63. Troikaa Company Information Table 64. Troikaa Business Overview Table 65. Troikaa Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Troikaa Antianginal Agents Product Portfolio Table 67. Troikaa Recent Developments Table 68. Taj pharmaceutical Company Information Table 69. Taj pharmaceutical Business Overview Table 70. Taj pharmaceutical Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Taj pharmaceutical Antianginal Agents Product Portfolio Table 72. Taj pharmaceutical Recent Developments Table 73. Square Pharmaceuticals Company Information Table 74. Square Pharmaceuticals Business Overview Table 75. Square Pharmaceuticals Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Square Pharmaceuticals Antianginal Agents Product Portfolio Table 77. Square Pharmaceuticals Recent Developments Table 78. Pharmaoffer.com Company Information Table 79. Pharmaoffer.com Business Overview Table 80. Pharmaoffer.com Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Pharmaoffer.com Antianginal Agents Product Portfolio Table 82. Pharmaoffer.com Recent Developments Table 83. Nesher Pharmaceuticals Company Information Table 84. Nesher Pharmaceuticals Business Overview Table 85. Nesher Pharmaceuticals Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Nesher Pharmaceuticals Antianginal Agents Product Portfolio Table 87. Nesher Pharmaceuticals Recent Developments Table 88. Mylan N.V. Company Information Table 89. Mylan N.V. Business Overview Table 90. Mylan N.V. Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Mylan N.V. Antianginal Agents Product Portfolio Table 92. Mylan N.V. Recent Developments Table 93. Ipca Laboratories Company Information Table 94. Ipca Laboratories Business Overview Table 95. Ipca Laboratories Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Ipca Laboratories Antianginal Agents Product Portfolio Table 97. Ipca Laboratories Recent Developments Table 98. Intas Pharmaceuticals Company Information Table 99. Intas Pharmaceuticals Business Overview Table 100. Intas Pharmaceuticals Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Intas Pharmaceuticals Antianginal Agents Product Portfolio Table 102. Intas Pharmaceuticals Recent Developments Table 103. Hikma Pharmaceuticals Company Information Table 104. Hikma Pharmaceuticals Business Overview Table 105. Hikma Pharmaceuticals Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Hikma Pharmaceuticals Antianginal Agents Product Portfolio Table 107. Hikma Pharmaceuticals Recent Developments Table 108. Globus Remedies Company Information Table 109. Globus Remedies Business Overview Table 110. Globus Remedies Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Globus Remedies Antianginal Agents Product Portfolio Table 112. Globus Remedies Recent Developments Table 113. Glenmark Pharmaceuticals Company Information Table 114. Glenmark Pharmaceuticals Business Overview Table 115. Glenmark Pharmaceuticals Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Glenmark Pharmaceuticals Antianginal Agents Product Portfolio Table 117. Glenmark Pharmaceuticals Recent Developments Table 118. Espero BioPharma Company Information Table 119. Espero BioPharma Business Overview Table 120. Espero BioPharma Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Espero BioPharma Antianginal Agents Product Portfolio Table 122. Espero BioPharma Recent Developments Table 123. Elite Pharmaceutical Solution Inc. Company Information Table 124. Elite Pharmaceutical Solution Inc. Business Overview Table 125. Elite Pharmaceutical Solution Inc. Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Elite Pharmaceutical Solution Inc. Antianginal Agents Product Portfolio Table 127. Elite Pharmaceutical Solution Inc. Recent Developments Table 128. Aurobindo Pharma Company Information Table 129. Aurobindo Pharma Business Overview Table 130. Aurobindo Pharma Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Aurobindo Pharma Antianginal Agents Product Portfolio Table 132. Aurobindo Pharma Recent Developments Table 133. Athenex Company Information Table 134. Athenex Business Overview Table 135. Athenex Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Athenex Antianginal Agents Product Portfolio Table 137. Athenex Recent Developments Table 138. AMRI Company Information Table 139. AMRI Business Overview Table 140. AMRI Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. AMRI Antianginal Agents Product Portfolio Table 142. AMRI Recent Developments Table 143. ACETO Company Information Table 144. ACETO Business Overview Table 145. ACETO Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. ACETO Antianginal Agents Product Portfolio Table 147. ACETO Recent Developments Table 148. Global Antianginal Agents Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 149. Global Antianginal Agents Sales by Region (2021-2026) & (K Units) Table 150. Global Antianginal Agents Sales Market Share by Region (2021-2026) Table 151. Global Antianginal Agents Sales by Region (2027-2032) & (K Units) Table 152. Global Antianginal Agents Sales Market Share by Region (2027-2032) Table 153. Global Antianginal Agents Revenue by Region (2021-2026) & (US$ Million) Table 154. Global Antianginal Agents Revenue Market Share by Region (2021-2026) Table 155. Global Antianginal Agents Revenue by Region (2027-2032) & (US$ Million) Table 156. Global Antianginal Agents Revenue Market Share by Region (2027-2032) Table 157. North America Antianginal Agents Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 158. North America Antianginal Agents Sales by Country (2021-2026) & (K Units) Table 159. North America Antianginal Agents Sales by Country (2027-2032) & (K Units) Table 160. North America Antianginal Agents Revenue by Country (2021-2026) & (US$ Million) Table 161. North America Antianginal Agents Revenue by Country (2027-2032) & (US$ Million) Table 162. Europe Antianginal Agents Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 163. Europe Antianginal Agents Sales by Country (2021-2026) & (K Units) Table 164. Europe Antianginal Agents Sales by Country (2027-2032) & (K Units) Table 165. Europe Antianginal Agents Revenue by Country (2021-2026) & (US$ Million) Table 166. Europe Antianginal Agents Revenue by Country (2027-2032) & (US$ Million) Table 167. Asia Pacific Antianginal Agents Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 168. Asia Pacific Antianginal Agents Sales by Country (2021-2026) & (K Units) Table 169. Asia Pacific Antianginal Agents Sales by Country (2027-2032) & (K Units) Table 170. Asia Pacific Antianginal Agents Revenue by Country (2021-2026) & (US$ Million) Table 171. Asia Pacific Antianginal Agents Revenue by Country (2027-2032) & (US$ Million) Table 172. South America Antianginal Agents Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 173. South America Antianginal Agents Sales by Country (2021-2026) & (K Units) Table 174. South America Antianginal Agents Sales by Country (2027-2032) & (K Units) Table 175. South America Antianginal Agents Revenue by Country (2021-2026) & (US$ Million) Table 176. South America Antianginal Agents Revenue by Country (2027-2032) & (US$ Million) Table 177. Middle East and Africa Antianginal Agents Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 178. Middle East and Africa Antianginal Agents Sales by Country (2021-2026) & (K Units) Table 179. Middle East and Africa Antianginal Agents Sales by Country (2027-2032) & (K Units) Table 180. Middle East and Africa Antianginal Agents Revenue by Country (2021-2026) & (US$ Million) Table 181. Middle East and Africa Antianginal Agents Revenue by Country (2027-2032) & (US$ Million) Table 182. Global Antianginal Agents Sales by Type (2021-2026) & (K Units) Table 183. Global Antianginal Agents Sales by Type (2027-2032) & (K Units) Table 184. Global Antianginal Agents Sales Market Share by Type (2021-2026) Table 185. Global Antianginal Agents Sales Market Share by Type (2027-2032) Table 186. Global Antianginal Agents Revenue by Type (2021-2026) & (US$ Million) Table 187. Global Antianginal Agents Revenue by Type (2027-2032) & (US$ Million) Table 188. Global Antianginal Agents Revenue Market Share by Type (2021-2026) Table 189. Global Antianginal Agents Revenue Market Share by Type (2027-2032) Table 190. Global Antianginal Agents Price by Type (2021-2026) & (US$/Unit) Table 191. Global Antianginal Agents Price by Type (2027-2032) & (US$/Unit) Table 192. Global Antianginal Agents Sales by Application (2021-2026) & (K Units) Table 193. Global Antianginal Agents Sales by Application (2027-2032) & (K Units) Table 194. Global Antianginal Agents Sales Market Share by Application (2021-2026) Table 195. Global Antianginal Agents Sales Market Share by Application (2027-2032) Table 196. Global Antianginal Agents Revenue by Application (2021-2026) & (US$ Million) Table 197. Global Antianginal Agents Revenue by Application (2027-2032) & (US$ Million) Table 198. Global Antianginal Agents Revenue Market Share by Application (2021-2026) Table 199. Global Antianginal Agents Revenue Market Share by Application (2027-2032) Table 200. Global Antianginal Agents Price by Application (2021-2026) & (US$/Unit) Table 201. Global Antianginal Agents Price by Application (2027-2032) & (US$/Unit) Table 202. Key Raw Materials Table 203. Raw Materials Key Suppliers Table 204. Antianginal Agents Distributors List Table 205. Antianginal Agents Customers List Table 206. Antianginal Agents Industry Trends Table 207. Antianginal Agents Industry Drivers Table 208. Antianginal Agents Industry Restraints Table 209. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Antianginal Agents Product Image Figure 5. Global Antianginal Agents Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Antianginal Agents Market Size (2021-2032) & (US$ Million) Figure 7. Global Antianginal Agents Sales (2021-2032) & (K Units) Figure 8. Global Antianginal Agents Average Price (US$/Unit) & (2021-2032) Figure 9. Beta Blockers Product Image Figure 10. Calcium Channel Blockers Product Image Figure 11. Nitrates Product Image Figure 12. Hospital Pharmacies Product Image Figure 13. Retail Pharmacies Product Image Figure 14. Online Pharmacies Product Image Figure 15. Global Antianginal Agents Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Antianginal Agents, Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Antianginal Agents Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Antianginal Agents Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Antianginal Agents Sales by Region in 2025 Figure 21. Global Antianginal Agents Revenue by Region in 2025 Figure 22. North America Antianginal Agents Market Size by Country in 2025 Figure 23. North America Antianginal Agents Sales Market Share by Country (2021-2032) Figure 24. North America Antianginal Agents Revenue Market Share by Country (2021-2032) Figure 25. United States Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Antianginal Agents Market Size by Country in 2025 Figure 28. Europe Antianginal Agents Sales Market Share by Country (2021-2032) Figure 29. Europe Antianginal Agents Revenue Market Share by Country (2021-2032) Figure 30. Germany Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Netherlands Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Asia Pacific Antianginal Agents Market Size by Country in 2025 Figure 36. Asia Pacific Antianginal Agents Sales Market Share by Country (2021-2032) Figure 37. Asia Pacific Antianginal Agents Revenue Market Share by Country (2021-2032) Figure 38. China Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Japan Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. South Korea Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. India Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Australia Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. China Taiwan Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Southeast Asia Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Southeast Asia Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South America Antianginal Agents Market Size by Country in 2025 Figure 47. South America Antianginal Agents Sales Market Share by Country (2021-2032) Figure 48. South America Antianginal Agents Revenue Market Share by Country (2021-2032) Figure 49. Mexico Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Brazil Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Argentina Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Middle East and Africa Antianginal Agents Market Size by Country in 2025 Figure 53. Middle East and Africa Antianginal Agents Sales Market Share by Country (2021-2032) Figure 54. Middle East and Africa Antianginal Agents Revenue Market Share by Country (2021-2032) Figure 55. Turkey Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Saudi Arabia Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. UAE Antianginal Agents Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Global Antianginal Agents Sales Market Share by Type (2021-2032) Figure 59. Global Antianginal Agents Revenue Market Share by Type (2021-2032) Figure 60. Global Antianginal Agents Price (US$/Unit) by Type (2021-2032) Figure 61. Global Antianginal Agents Sales Market Share by Application (2021-2032) Figure 62. Global Antianginal Agents Revenue Market Share by Application (2021-2032) Figure 63. Global Antianginal Agents Price (US$/Unit) by Application (2021-2032) Figure 64. Antianginal Agents Value Chain Figure 65. Antianginal Agents Production Mode & Process Figure 66. Direct Comparison with Distribution Share Figure 67. Distributors Profiles Figure 68. Antianginal Agents Industry Opportunities and Challenges

Scope & coverage.

Types
  • Beta Blockers
  • Calcium Channel Blockers
  • Nitrates
Applications
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Companies covered
  • Teva
  • Sun Pharmaceutical
  • Shandong Fangming Pharmaceutical Group
  • Sandoz
  • ReYoung Pharmaceutical
  • Merck
  • Pfizer
  • AstraZeneca
  • Unique Pharmaceuticals
  • Troikaa
  • Taj pharmaceutical
  • Square Pharmaceuticals
  • Pharmaoffer.com
  • Nesher Pharmaceuticals
  • Mylan N.V.
  • Ipca Laboratories
  • Intas Pharmaceuticals
  • Hikma Pharmaceuticals
  • Globus Remedies
  • Glenmark Pharmaceuticals
  • Espero BioPharma
  • Elite Pharmaceutical Solution Inc.
  • Aurobindo Pharma
  • Athenex
  • AMRI
  • ACETO

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Antianginal Agents Market Size (2021-2032)
  4. 2.2.2 Global Antianginal Agents Sales (2021-2032)
  5. 2.2.3 Global Antianginal Agents Market Average Price (2021-2032)
  6. 2.3 Antianginal Agents by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Beta Blockers
  9. 2.3.3 Calcium Channel Blockers
  10. 2.3.4 Nitrates
  11. 2.4 Antianginal Agents by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Hospital Pharmacies
  14. 2.4.3 Retail Pharmacies
  15. 2.4.4 Online Pharmacies
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Antianginal Agents Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Antianginal Agents Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Antianginal Agents Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Antianginal Agents Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Antianginal Agents Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Antianginal Agents, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Antianginal Agents, Product Type & Application
  8. 3.8 Global Manufacturers of Antianginal Agents, Established Date
  9. 3.9 Global Antianginal Agents Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Teva
  2. 4.1.1 Teva Company Information
  3. 4.1.2 Teva Business Overview
  4. 4.1.3 Teva Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Teva Antianginal Agents Product Portfolio
  6. 4.1.5 Teva Recent Developments
  7. 4.2 Sun Pharmaceutical
  8. 4.2.1 Sun Pharmaceutical Company Information
  9. 4.2.2 Sun Pharmaceutical Business Overview
  10. 4.2.3 Sun Pharmaceutical Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sun Pharmaceutical Antianginal Agents Product Portfolio
  12. 4.2.5 Sun Pharmaceutical Recent Developments
  13. 4.3 Shandong Fangming Pharmaceutical Group
  14. 4.3.1 Shandong Fangming Pharmaceutical Group Company Information
  15. 4.3.2 Shandong Fangming Pharmaceutical Group Business Overview
  16. 4.3.3 Shandong Fangming Pharmaceutical Group Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Shandong Fangming Pharmaceutical Group Antianginal Agents Product Portfolio
  18. 4.3.5 Shandong Fangming Pharmaceutical Group Recent Developments
  19. 4.4 Sandoz
  20. 4.4.1 Sandoz Company Information
  21. 4.4.2 Sandoz Business Overview
  22. 4.4.3 Sandoz Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Sandoz Antianginal Agents Product Portfolio
  24. 4.4.5 Sandoz Recent Developments
  25. 4.5 ReYoung Pharmaceutical
  26. 4.5.1 ReYoung Pharmaceutical Company Information
  27. 4.5.2 ReYoung Pharmaceutical Business Overview
  28. 4.5.3 ReYoung Pharmaceutical Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 ReYoung Pharmaceutical Antianginal Agents Product Portfolio
  30. 4.5.5 ReYoung Pharmaceutical Recent Developments
  31. 4.6 Merck
  32. 4.6.1 Merck Company Information
  33. 4.6.2 Merck Business Overview
  34. 4.6.3 Merck Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Merck Antianginal Agents Product Portfolio
  36. 4.6.5 Merck Recent Developments
  37. 4.7 Pfizer
  38. 4.7.1 Pfizer Company Information
  39. 4.7.2 Pfizer Business Overview
  40. 4.7.3 Pfizer Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Pfizer Antianginal Agents Product Portfolio
  42. 4.7.5 Pfizer Recent Developments
  43. 4.8 AstraZeneca
  44. 4.8.1 AstraZeneca Company Information
  45. 4.8.2 AstraZeneca Business Overview
  46. 4.8.3 AstraZeneca Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 AstraZeneca Antianginal Agents Product Portfolio
  48. 4.8.5 AstraZeneca Recent Developments
  49. 4.9 Unique Pharmaceuticals
  50. 4.9.1 Unique Pharmaceuticals Company Information
  51. 4.9.2 Unique Pharmaceuticals Business Overview
  52. 4.9.3 Unique Pharmaceuticals Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Unique Pharmaceuticals Antianginal Agents Product Portfolio
  54. 4.9.5 Unique Pharmaceuticals Recent Developments
  55. 4.10 Troikaa
  56. 4.10.1 Troikaa Company Information
  57. 4.10.2 Troikaa Business Overview
  58. 4.10.3 Troikaa Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Troikaa Antianginal Agents Product Portfolio
  60. 4.10.5 Troikaa Recent Developments
  61. 4.11 Taj pharmaceutical
  62. 4.11.1 Taj pharmaceutical Company Information
  63. 4.11.2 Taj pharmaceutical Business Overview
  64. 4.11.3 Taj pharmaceutical Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Taj pharmaceutical Antianginal Agents Product Portfolio
  66. 4.11.5 Taj pharmaceutical Recent Developments
  67. 4.12 Square Pharmaceuticals
  68. 4.12.1 Square Pharmaceuticals Company Information
  69. 4.12.2 Square Pharmaceuticals Business Overview
  70. 4.12.3 Square Pharmaceuticals Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Square Pharmaceuticals Antianginal Agents Product Portfolio
  72. 4.12.5 Square Pharmaceuticals Recent Developments
  73. 4.13 Pharmaoffer.com
  74. 4.13.1 Pharmaoffer.com Company Information
  75. 4.13.2 Pharmaoffer.com Business Overview
  76. 4.13.3 Pharmaoffer.com Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Pharmaoffer.com Antianginal Agents Product Portfolio
  78. 4.13.5 Pharmaoffer.com Recent Developments
  79. 4.14 Nesher Pharmaceuticals
  80. 4.14.1 Nesher Pharmaceuticals Company Information
  81. 4.14.2 Nesher Pharmaceuticals Business Overview
  82. 4.14.3 Nesher Pharmaceuticals Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Nesher Pharmaceuticals Antianginal Agents Product Portfolio
  84. 4.14.5 Nesher Pharmaceuticals Recent Developments
  85. 4.15 Mylan N.V.
  86. 4.15.1 Mylan N.V. Company Information
  87. 4.15.2 Mylan N.V. Business Overview
  88. 4.15.3 Mylan N.V. Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Mylan N.V. Antianginal Agents Product Portfolio
  90. 4.15.5 Mylan N.V. Recent Developments
  91. 4.16 Ipca Laboratories
  92. 4.16.1 Ipca Laboratories Company Information
  93. 4.16.2 Ipca Laboratories Business Overview
  94. 4.16.3 Ipca Laboratories Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Ipca Laboratories Antianginal Agents Product Portfolio
  96. 4.16.5 Ipca Laboratories Recent Developments
  97. 4.17 Intas Pharmaceuticals
  98. 4.17.1 Intas Pharmaceuticals Company Information
  99. 4.17.2 Intas Pharmaceuticals Business Overview
  100. 4.17.3 Intas Pharmaceuticals Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Intas Pharmaceuticals Antianginal Agents Product Portfolio
  102. 4.17.5 Intas Pharmaceuticals Recent Developments
  103. 4.18 Hikma Pharmaceuticals
  104. 4.18.1 Hikma Pharmaceuticals Company Information
  105. 4.18.2 Hikma Pharmaceuticals Business Overview
  106. 4.18.3 Hikma Pharmaceuticals Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Hikma Pharmaceuticals Antianginal Agents Product Portfolio
  108. 4.18.5 Hikma Pharmaceuticals Recent Developments
  109. 4.19 Globus Remedies
  110. 4.19.1 Globus Remedies Company Information
  111. 4.19.2 Globus Remedies Business Overview
  112. 4.19.3 Globus Remedies Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Globus Remedies Antianginal Agents Product Portfolio
  114. 4.19.5 Globus Remedies Recent Developments
  115. 4.20 Glenmark Pharmaceuticals
  116. 4.20.1 Glenmark Pharmaceuticals Company Information
  117. 4.20.2 Glenmark Pharmaceuticals Business Overview
  118. 4.20.3 Glenmark Pharmaceuticals Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Glenmark Pharmaceuticals Antianginal Agents Product Portfolio
  120. 4.20.5 Glenmark Pharmaceuticals Recent Developments
  121. 4.21 Espero BioPharma
  122. 4.21.1 Espero BioPharma Company Information
  123. 4.21.2 Espero BioPharma Business Overview
  124. 4.21.3 Espero BioPharma Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Espero BioPharma Antianginal Agents Product Portfolio
  126. 4.21.5 Espero BioPharma Recent Developments
  127. 4.22 Elite Pharmaceutical Solution Inc.
  128. 4.22.1 Elite Pharmaceutical Solution Inc. Company Information
  129. 4.22.2 Elite Pharmaceutical Solution Inc. Business Overview
  130. 4.22.3 Elite Pharmaceutical Solution Inc. Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Elite Pharmaceutical Solution Inc. Antianginal Agents Product Portfolio
  132. 4.22.5 Elite Pharmaceutical Solution Inc. Recent Developments
  133. 4.23 Aurobindo Pharma
  134. 4.23.1 Aurobindo Pharma Company Information
  135. 4.23.2 Aurobindo Pharma Business Overview
  136. 4.23.3 Aurobindo Pharma Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  137. 4.23.4 Aurobindo Pharma Antianginal Agents Product Portfolio
  138. 4.23.5 Aurobindo Pharma Recent Developments
  139. 4.24 Athenex
  140. 4.24.1 Athenex Company Information
  141. 4.24.2 Athenex Business Overview
  142. 4.24.3 Athenex Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  143. 4.24.4 Athenex Antianginal Agents Product Portfolio
  144. 4.24.5 Athenex Recent Developments
  145. 4.25 AMRI
  146. 4.25.1 AMRI Company Information
  147. 4.25.2 AMRI Business Overview
  148. 4.25.3 AMRI Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  149. 4.25.4 AMRI Antianginal Agents Product Portfolio
  150. 4.25.5 AMRI Recent Developments
  151. 4.26 ACETO
  152. 4.26.1 ACETO Company Information
  153. 4.26.2 ACETO Business Overview
  154. 4.26.3 ACETO Antianginal Agents Sales, Revenue and Gross Margin (2021-2026)
  155. 4.26.4 ACETO Antianginal Agents Product Portfolio
  156. 4.26.5 ACETO Recent Developments
5 Global Antianginal Agents Market Scenario by Region
  1. 5.1 Global Antianginal Agents Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Antianginal Agents Sales by Region: 2021-2032
  3. 5.2.1 Global Antianginal Agents Sales by Region: 2021-2026
  4. 5.2.2 Global Antianginal Agents Sales by Region: 2027-2032
  5. 5.3 Global Antianginal Agents Revenue by Region: 2021-2032
  6. 5.3.1 Global Antianginal Agents Revenue by Region: 2021-2026
  7. 5.3.2 Global Antianginal Agents Revenue by Region: 2027-2032
  8. 5.4 North America Antianginal Agents Market Facts & Figures by Country
  9. 5.4.1 North America Antianginal Agents Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Antianginal Agents Sales by Country (2021-2032)
  11. 5.4.3 North America Antianginal Agents Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Antianginal Agents Market Facts & Figures by Country
  15. 5.5.1 Europe Antianginal Agents Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Antianginal Agents Sales by Country (2021-2032)
  17. 5.5.3 Europe Antianginal Agents Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Antianginal Agents Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Antianginal Agents Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Antianginal Agents Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Antianginal Agents Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Antianginal Agents Market Facts & Figures by Country
  35. 5.7.1 South America Antianginal Agents Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Antianginal Agents Sales by Country (2021-2032)
  37. 5.7.3 South America Antianginal Agents Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Antianginal Agents Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Antianginal Agents Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Antianginal Agents Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Antianginal Agents Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Antianginal Agents Sales by Type (2021-2032)
  2. 6.1.1 Global Antianginal Agents Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Antianginal Agents Sales Market Share by Type (2021-2032)
  4. 6.2 Global Antianginal Agents Revenue by Type (2021-2032)
  5. 6.2.1 Global Antianginal Agents Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Antianginal Agents Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Antianginal Agents Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Antianginal Agents Sales by Application (2021-2032)
  2. 7.1.1 Global Antianginal Agents Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Antianginal Agents Sales Market Share by Application (2021-2032)
  4. 7.2 Global Antianginal Agents Revenue by Application (2021-2032)
  5. 7.2.1 Global Antianginal Agents Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Antianginal Agents Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Antianginal Agents Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Antianginal Agents Value Chain Analysis
  2. 8.1.1 Antianginal Agents Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Antianginal Agents Production Mode & Process
  5. 8.2 Antianginal Agents Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Antianginal Agents Distributors
  8. 8.2.3 Antianginal Agents Customers
9 Global Antianginal Agents Analyzing Market Dynamics
  1. 9.1 Antianginal Agents Industry Trends
  2. 9.2 Antianginal Agents Industry Drivers
  3. 9.3 Antianginal Agents Industry Opportunities and Challenges
  4. 9.4 Antianginal Agents Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst